Lifecore Biomedical signs site-transfer agreement supporting pharma commercialization
Lifecore Biomedical (LFCR) signed an agreement for a commercial site transfer supporting a global pharmaceutical company’s tech transfer and commercial manufacturing of a currently marketed drug product.
Lifecore Biomedical said the program is positioned to become one of its largest contracts and that the agreement supports tech transfer and commercial manufacturing of a currently marketed drug product. The company said the program is expected to contribute to 2028 commercial revenues. CHASKA, Minn., Sept. 02, 2026 (GLOBE NEWSWIRE…)